FLIR Cancelling Contract With X.Labs / Feevr

By John Honovich, Published May 20, 2020, 07:39am EDT

While X.Labs announced the signing of a new agreement with FLIR on May 12, 2020, FLIR said, in response, on May 18, 2020, that they had cancelled a previous contract and are in the process of cancelling a second contract.

IPVM Image

Fever Detection Controversy

The use of fever, or in the case of X.Labs, "feevr" detectors are growing along with increasing controversy. For example, the Washington Post declared last week "Thermal scanners are the latest technology being deployed to detect the coronavirus. But they don’t really work."

X.Labs ********* ******

****** ****, *.**** "*****" product *** ****** ********* for *** ********* ** a "***** ********* ******" with ******* ******** (±*.*°*) which ** ******* **** Dahua, ****, *********, ***. at * ******** ** those ********* ******, ** they ********* ** *****"***** ** ***********" ********.

Accuracy ********

**** ** **** ***** is **** *.**** **** they *** ***** ***** *** *** ********** ******* *** ~$***,*** ****, *** ************** ***** *********** / 'feevr' ******** ******* *** accuracy ** ********* ** just ~±*°*.

X.Labs ************

** *** **, ****,*.**** *********"*** ******* ** * product ****** ********* **** FLIR ********** *******"*** *** ************ ******** no ***** *** **** from ****.

*.**** ***, ** ********, recently**** * ******* ***********:

*** **** *** **** FLIR ****** * *** agreement **** *** ******* in ***** *** **** is ***** ** **** effect. **** **** ** attached ** ** ******* to *** ******

*******, ***** *** ** copy *** ******* ********* any **** ********* ** the ****** / *********.

*** *** *** ** SDS, *****'* ******* ***********, who ** **** ***.**** ***** ******, ******************:

IPVM Image

FLIR **** **********

*******, ****, ** *** 18, ****, ********* ** IPVM's ******* ** *.**** announcement ***** **** ******.**** ******** ** ****** Relations *** *************:

** *** *** ******** contract **** ***** ********/***** that ** ********* *** I *** ******* ** are ** *** ******* of ********** * ****** contract **** **** ***.

*.**** *** *** ******* to ****'* ******* *** comment ** ****'* ********.

Other ******* ********* **** *** *** *** '*****' ********* *******

********, *** *** ***** company,*****, **** *** **** publicly ********* '*****' ********* using * **** *** Pro ******** ******* ***** marketing ************ * ********** *************** **** **** *** endorse ** ******* ***** app:

IPVM Image

FLIR *** *** *** ******** *** ***** *********

**** *** **** ********** from *** ***** ** the *********** ******** **** FLIR *** *** ******* are *** ******** *** 'fever' ********* ***** ** FLIR's *** ****-******** ******** specifications.

***** *** ****** ** certainly ******* *** ********* to ****** *** **** the ****** ** ***********, as *** ********** **** so ***** ****** **** week, *** ******* ** whether ***** ******* "***'* really ****."

Comments (22)

IPVM Image

******** ***** ******** ***'* really **** ******, *** we're *** ******* ****. Fever *********, **** **** masks, ****** ****** ******** is *** **** ** a ***** ******** ***** and **'* **** *********. We *** **** ** be **** ******* **** usual ******* **** ********* enemy **** ** *****-**, and *** ** ***** solutions ***** **** ********* awareness ********** ** *** arguable *************.

*** *** **** ******* guidance ** *** ******** risk ** ******* ******* to ***.

*** *********** ******* | CDC

* ** *** ** favor ** **** **** gestures **** ******* **** have * ******** ****** on **********/*********.

*** ** ***** ********* raise **** ********* ********* regardless ** *** ******** effectiveness.

*** ******* ********:

*. ** *** ****** a ******** ****** ****** to ** **** ******** in ***** *****, ** poses * ****, *.*., if ****** ******* **** fevers *** ***** ** get ******, **** *** be **** ****** ** maintain ****** ********, **** hands, ***.

*. ** ****** ****** to ****** ******** **** are ** ********* ** possible, *.*., ** * 'fever ******' ******** **% of ****** *** ******* captures **** **% ** should *** ** ********** those *********** *** ****** the ***** ** ***** ones **** ******* **** vs *****.

*’* *** **** ** makes ***** **** **** 100% ******** ***** **** up ** **% ** COVID ******** *** ************. Would *** ****** **’* of ********* ** ** Intrusion ****** **** * 20% ********* ****?

********** * ***** **** the **** ***** ********* solutions *** ****** ** do **** ****** **** good ** ****** * false ***** ** ******** as *** **** ***** point. **** **** *** for *** ******** ******.

*** * **** ** 80% ************? *** **** today **’* **% ************, up **** **% ** April.

**** **’* ********* **** is ** ******* *** is ********* ** ********* demographics. ** *** *** detection ** **** ****** might ****** ** ***** than **** *******.

**’* ********* ** *** agree ** **** ****, it’s ** *** ***** of **** ********** ********** of **** **** ** thermal *********.

** *** ******** *** that ****** **% **** Asymptomatic ** **** ********. Presumably ***** **** **** be ******** **** *** pre-symptomatic. * ***’* ***** you **** **** *** to ** ******** ****** of **** % ***** present ******* * *****, but *** ***** ** it ** *********** (*** I ******* * ********). So *** ****** ** that ************* *** (***-)*** to ******* **** **** can ***** **** **** a *** *******.

**** ** *** *** info ******?

****** ***.

** ** ************* **** info **** **** ******* in ****.

“*** *****-**, **** ** date ******* **** **% of ********** *** **** or ************, **% *** severe *********, ********* ****** and *% *** ******** infections”

**% ** ******** **** didn’t ******* ******* *************** and ******. **** ** not ** *** **** were *** ************, ** absolutely **** ****’* *** the ****. **** ** get **** **** ******, stay **** *** ******* (considered **** *****). **** guidelines *** *** **** we **** ** ** on *** ** ******* for *** ****** ** 65% ***********.

* ***** ** *** agree ** ** **** enough ** ******* ****** every ****** ** ***** a **** $** *********** and ****** **** ** stay ** **** ** they **** * ***** or ***** ******** ;-)

** ***, ****** :)

*** ********** ********* *** all **** *** ***. This ******* ******** ******** different ********** ******** ***************-**: **** ********** *** asymptomatic? - ******** *% ** ** the **% ****** **** WHO. ***** ** ** that ****** ****** ***** at **** ***** ***** may **** ** **** never **** *** ****.

** *** ****** ******* 75% *** *** ***** only **%. ** ****** combine **** ** **** into * ****** ******* that ******* ***%***** *** marketing *****.

******, ****** ****** *** excellence.

**** ** ******* ** do ******* **** ** comes ** ********** *** spread ** *****-**?

**** ** ************* ******** * *************'* ***********

*** **** ** ******* these ******? ** ******* the ****** ** ********** measures ** **** * significant ******. ****** - the ****** ***** *** no ******** - *** had ** ******* ** new ***** ******* *** 30 *** *** ** and *** ***** *** now ******* ** *** the ***** ** ***** Korea, * *** ****** country.

IPVM Image

* ******* ****** ** relying ** **** ********... So *** **** ******** should **, **** ** the ********** ** ****** of *** ********. ******'* plan ** ** ********** the '**********' ***** *** 'non-vulnerable' ****** ***** **** on ****** ***** *****.

* ** *** ****** his ******** ** *******....

* ** ****** ****** that ** ******** *** positions ** *** *** best ************* ** *** to ****** **** ******.

*** ***, * **** math ** ****** **** anything **** **** ** comes ** ********** ******** - ** **** ** it ** ********* ****** and *********.

***** ***** **** ** a ******** ****** *** get ** *** *******.

******* ****** ***** ***** & ***** ******** ** CBS****************.

** **** *** ***. He ***** ** **** this ********** ** ******* that *** **** ** looking ** *** ************ like *****. *** *** TSA ****** ***** ** use * ****** **** the *** *** ******* stated ** *** ********...***** on ******* ***.

Read this IPVM report for free.

This article is part of IPVM's 6,649 reports, 895 tests and is only available to members. To get a one-time preview of our work, enter your work email to access the full article.

Already a member? Login here | Join now
Loading Related Reports